Welichem Biotech Inc.

Welichem Biotech Inc.

April 13, 2007 13:59 ET

Welichem Biotech to Report to Major Anti-Cancer Conference

BURNABY, BRITISH COLUMBIA--(CCNMatthews - April 13, 2007) - Welichem Biotech Inc. (TSX VENTURE:WBI) is pleased to announce that its presentation, entitled "Insight into the biological activity of a naturally-derived dithiopyrrolone with a wide spectrum activity against metastatic cancer models", will be made at the 2007 AACR (American Association of Cancer Research) annual meeting, to be held at the convention centre in Los Angles from April 14-18. The AACR meeting is the largest cancer research meeting in the world, with more than 10,000 attendees from academic institutes, government agencies and industry.

Welichem will present on April 17 in a "Late-Breaking Session". Dr. Moulay Alaoui-Jamali, a member of Welichem's Scientific Advisory Board and a Professor at McGill University, and Dr. Liren Tang, Head of Life Sciences at Welichem, will make the presentation of behalf of the Company.

Welichem will report preclinical and biochemical data based on its novel anti-cancer molecule (WBI-2100). With structural features distinct from those of other anti-cancer agents, WBI-2100 has been demonstrated to have strong activity against advanced preclinical cancer models, including melanoma and breast, lung, pancreatic and liver cancer. WBI-2100 also shows anti-metastatic (anti-tumour spreading) activity in three mouse metastatic models, human breast cancer, lung Lewis carcinoma and B16 melanoma models. Welichem expects its proprietary naturally-derived small molecule with anti-cancer properties to support a potential clinical utility to fight advanced human cancer.


York Yingping Guo, President and Chief Executive Officer

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs to combat psoriasis, autoimmune and inflammatory diseases, and cancer. The Company is located in Burnaby, British Columbia. Its stock is traded on the Toronto Venture Stock Exchange under the symbol WBI.V.

This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Contact Information